BidaskClub Lowers Kindred Biosciences (KIN) to Strong Sell

BidaskClub lowered shares of Kindred Biosciences (NASDAQ:KIN) from a sell rating to a strong sell rating in a research note published on Thursday morning, BidAskClub reports.

Other equities analysts have also issued reports about the company. Aegis started coverage on Kindred Biosciences in a research note on Wednesday, April 10th. They set a buy rating and a $16.00 price target for the company. Cantor Fitzgerald reaffirmed a buy rating and set a $25.00 price target on shares of Kindred Biosciences in a research note on Tuesday, March 5th. ValuEngine lowered Kindred Biosciences from a strong-buy rating to a buy rating in a research note on Monday, March 11th. Lake Street Capital decreased their price target on Kindred Biosciences from $30.00 to $12.00 and set a buy rating for the company in a research note on Thursday, March 7th. Finally, HC Wainwright reaffirmed a buy rating and set a $19.00 price target on shares of Kindred Biosciences in a research note on Thursday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Kindred Biosciences currently has an average rating of Buy and a consensus target price of $17.82.

Shares of KIN stock opened at $8.74 on Thursday. Kindred Biosciences has a 12-month low of $8.04 and a 12-month high of $15.75.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). The business had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.44 million. On average, analysts anticipate that Kindred Biosciences will post -1.54 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of Kindred Biosciences by 24.6% during the 3rd quarter. Legal & General Group Plc now owns 4,659 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 920 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Kindred Biosciences by 362.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 7,563 shares during the last quarter. Meeder Asset Management Inc. lifted its position in shares of Kindred Biosciences by 16.7% during the 1st quarter. Meeder Asset Management Inc. now owns 11,922 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,706 shares during the last quarter. Grassi Investment Management acquired a new stake in shares of Kindred Biosciences during the 4th quarter valued at $126,000. Finally, Teton Advisors Inc. acquired a new stake in shares of Kindred Biosciences during the 4th quarter valued at $142,000. Institutional investors own 56.83% of the company’s stock.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.